| Document ID (ISN) | 112282 |
| CIS number |
12-0037 |
| ISBN(s) |
978-3-7776-1480-9 |
| Year |
2006 |
| Convention or series no. |
BUA Report 256
|
| Author(s) |
Gesellschaft Deutscher Chemiker (GDCh), Advisory Committee on Existing Chemicals (BUA) |
| Title |
2-Chlorobenzothiazole |
| Bibliographic information |
Hirzel Verlag, Birkenwaldstrasse 44, 70191 Stuttgart, Germany, 2006. xiii, 34p. Bibl.ref. Price: EUR 36.00. |
| Internet access |
BUA_Report_256_Summary_[INTERNET_FREE_ACCESS] [in English]
BUA_Report_256_[BUY_THIS_DOCUMENT].pdf [in English]
|
| Abstract |
Conclusions of this criteria document which reflects the state of knowledge as of February 2005: No studies are available on the metabolism of 2-chlorobenzothiazole or its mechanism of action. The 4-hour LC50 for rats is more than 79 mg 2-chlorobenzothiazole/m3. The oral LD50 for rats is between 100 and 200 mg/kg, being 50 mg/kg for mice. Acute symptoms of poisoning after inhalation and oral uptake are behavioural disturbances, breathing difficulties and spasms. During inhalation, irritation occurs to the conjunctiva of the eye and the nasal mucosa, whereas oral administration causes local irritation of the gastro-intestinal mucosa. Regardless of the exposure route, necropsy reveals emphysematous or edaematous lung lesions, increased iron deposits in the liver, liver necrosis and inflammation of the kidneys. Studies with repeated administration are lacking. The results of the mutagenicity test with Salmonella typhimurium give no indication of a mutagenic potential even in the cytotoxic range. Other findings are discussed. |
| Descriptors (primary) |
Germany; benzothiazoles; chlorinated organic compounds; toxicology; ecotoxicology |
| Descriptors (secondary) |
animal experiments; literature survey; criteria document |
| Document type |
B - Chemical safety information sheets |
| Subject(s) |
Toxic and dangerous substances
|
| Broad subject area(s) |
Chemical safety
|
| Browse category(ies) |
Toxicology
Heterocyclic compounds
|
